PharmaVentures appoints senior director

Paul Phull will develop corporate advisory business

PharmaVentures, based in Oxford, UK, has hired Paul Phull as senior director to develop its corporate advisory business.

PharmaVentures is an international corporate advisory firm supporting its clients’ growth ambitions through licensing, joint ventures and M&A in the healthcare industry. The company works for a variety of clients from start-ups to global pharmaceutical corporations, their advisers, investment companies and government bodies.

Phull joins the company from Sinclair Pharma, a specialist pharmaceutical company in the UK, where he was responsible for the development of the international business. He has significant deal making and corporate transaction experience with a broad range of companies in Europe, US, Japan, India and Asia in a number of therapeutic areas.

You may also like

Manufacturing

Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges

CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth
Finance

Pfizer clinches $10bn deal to acquire weight-loss biotech Metsera after bidding war with Novo Nordisk

Metsera says that it has opted for Pfizer's revised deal after antitrust concerns surrounding rival Novo's bid for the biotech
Finance

Pfizer denied restraining order on rival Novo Nordisk in GLP-1 bidding war

The Delaware Chancery Judge rejected Pfizer's request for a temporary restraining order, arguing that the company's objections to Novo's proposed deal weren't a legitimate reason for stopping the competitor's offer
Finance

Custom Pharmaceuticals launches new company to foster breakthrough drug development and strategic partnerships

Custom Pharmaceuticals Ltd has launched Centrix Pharma Solutions, a new company dedicated to accelerating drug product development through collaboration with biotech firms and academic research
Finance

Metsera declares $10bn Novo deal "superior" after Pfizer files second lawsuit in GLP-1 row

Metsera has said Novo Nordisk’s revised offer is a “superior proposal” to Pfizer’s, escalating a high-stakes legal and acquisition battle and where Pfizer has filed a second lawsuit accusing Novo of anticompetitive behaviour and Metsera of collusion
Finance

Kimberley-Clark to acquire Tylenol maker Kenvue in landmark $40bn deal

The transaction brings together two iconic American companies to create a combined portfolio of complementary products, including 10 billion-dollar brands, that touch nearly half the global population through every stage of life
Finance

Pfizer sues Metsera and Novo Nordisk over alleged breach of merger agreement

Pfizer has filed a lawsuit against Metsera, its Board of Directors and Novo Nordisk, alleging breach of contract, fiduciary duty and interference following Metsera’s decision to pursue a rival offer that Pfizer claims is “illegal”
Subscribe now